Endothelin antagonism in end-organ damage of spontaneously hypertensive rats: Comparison with angiotensin-converting enzyme inhibition and calcium antagonism

Hypertension

Volumn 28, Issue 3, 1996, Pages 379-385

  Karam, Habib ^a   Heudes, Didier ^b   Bruneval, Patrick ^b   Gonzales, Marie Françoise ^c   Löffler, Bernd Michael ^a   Clozel, Martine ^a   Clozel, Jean Paul ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HÔPITAL BROUSSAIS   (France)

^c INSERM   (France)

Author keywords

angiotensin II; bosentan; enalapril; endothelin; kidney; mibefradil

Indexed keywords

ANGIOTENSIN; BOSENTAN; CALCIUM ANTAGONIST; CREATININE; ENALAPRIL; ENDOTHELIN; ENDOTHELIN A; ENDOTHELIN B RECEPTOR; MIBEFRADIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM ANTAGONISM; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MECHANISM; ENZYME INHIBITION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HYPERTENSION; KIDNEY DISEASE; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0029823910     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.3.379     Document Type: Article

References (57)

1. Frohlich ED. Hemodynamics and other determinants in development of left ventricular hypertrophy. Fed Proc. 1983;42:2709-2715.
2. Wicker P, Tarazi RC, Kobayashi K. Coronary blood flow during the development and regression of left ventricular hypertrophy in renovascular hypertensive rats. Am J Cardiol. 1983;51:1744-1749.
3. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure-overloaded, hypertrophied non-human primate myocardium. Circ Res. 1988;62:757-765.
4. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-1364.
5. Folkow B, Hallbäck M, Lundgren Y, Sivertsson R, Weiss L. Importance of adaptive changes in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats. Circ Res. 1973;32(suppl I):I-2-I-13.
6. Berry C, Greenwald SE. Effect of hypertension on the static mechanical properties and chemical composition of the rat aorta. Cardiovasc Res. 1976;10:437-451.
7. Olson JL, Wilson SK, Heptinstall RH. Relation of glomerular injury to preglomerular resistance in experimental hypertension. Kidney Int. 1986;29:849-857.
8. Norman RAJ, Enobakhare JA, DeClue JW, Douglas BH, Guyton AC. Arterial pressure-urinary output relationship in hypertensive rats. Am J Physiol. 1978;234:R98-R103.
9. Tsoporis J, Leenen FHH. Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension. 1988; 11:376-386.
10. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A. 1982;79:3310-3314.
11. Sen S, Bumpus FM. Collagen synthesis in development and reversal of cardiac hypertrophy in spontaneously hypertensive rats. Am J Cardiol. 1979;44:954-958.
12. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension. 1987;9:178-187.
13. Heeg JE, De Jong PE, Van der Hem GK, De Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int. 1987;32:78-83.
14. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992;90:766-771.
15. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi K, Marumo F. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res. 1991;69:209-215.
16. Guarda E, Myers PR, Brilla CG, Tyagi SC, Weber KT. Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Cardiovasc Res. 1993;27:1004-1008.
17. Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev. 1993;73:375-411.
18. Ohno A, Naruse M, Kato S, Hosaka M, Naruse K, Demura H, Sugino N. Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in spontaneously hypertensive rats. J Hypertens. 1992:10:781-785.
19. Okamoto K. Spontaneous hypertension in rats. Int Rev Exp Pathol. 1969;7:227-270.
20. Trippodo N, Frolich E. Similarities of genetic (spontaneous) hypertension: man and rat. Circ Res. 1981;48:309-319.
21. Arendshorst WJ, Beierwaltes WH. Renal and nephron hemodynamics in spontaneously hypertensive rats. Am J Physiol. 1979; 236:F246-F251.
22. Clozel M, Breu V, Gray GA, Kalina B, Löffler B-M, Bum K, Cassai J-M, Hirth G, Müller M, Neidhart W, Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270: 228-235.
23. Clozel J-P, Osterrieder W, Kleinbloesem CH, Welker HA, Schläppi B, Tudor R, Hefti F, Schmitt R, Eggers H. Ro 40-5967: a new non-dihydropyridine calcium antagonist. Cardiovasc Drugs Rev. 1991; 9:4-17.
24. 2+ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy. Eur J Pharmacol. 1991;196:205.
25. 2+ channels by Ro 40-5967. Circ Res. 1994;75:144-148.
26. Hefti F, Clozel J-P, Osterrieder W. Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2[[3-(2-benzimidazolyl)propyl ]methylamino]ethyl] - 6 - fluoro - 1,2,3,4 - tetrahydro - 1 - isopropyl -2-naphtyl methoxyacetate dihydrochloride in rat models of hypertension. Arzneimittelforschung. 1990;40:417-421.
27. Ménard J, Catt KJ. Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin I. Endocrinology. 1972;90:422-430.
28. Löffler B-M, Maire J-P. Radioimmunological determination of endothelin peptides in human plasma: a methodological approach. Endothelium. 1994:1:273-286.
29. Véniant M, Heudes D, Clozel J-P, Bruneval P, Ménard J. Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney Int. 1994;46:421-429.
30. Li J-S, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension. 1995;25(part 1):495-500.
31. Larivière R, Sventek P, Thibault G, Schiffrin EL. Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA/ETB endothelin receptor antagonist bosentan. Can J Physiol Pharmacol. 1995;73:390-398.
32. Löffler B-M, Breu V, Clozel M. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 in endothelin levels in rat plasma. FEBS Lett. 1993;333:108-110.
33. B receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465.
34. Larivière R, Sventek P, Schiffrin EL. Expression of endothelin-1 gene in blood vessels of adult spontaneously hypertensive rats. Life Sci. 1995;56:1889-1896.
35. Pfeffer MA, Frohlich ED. Hemodynamic and myocardial function in young and old normotensive and spontaneously hypertensive rats. Circ Res. 1973;32(suppl I):I-28-I-38.
36. Feld LG, Zamlauslki-Tucker MJ, Springate JE, Van Liew JB. Single nephron hemodynamics in spontaneously hypertensive rats. Proc Soc Exp Biol Med. 1995;209:185-189.
37. Dilley JR, Stier CT, Arendshorst WJ. Abnormalities in glomerular function in rats developing spontaneous hypertension. Am J Physiol. 1984;246:F12-F20.
38. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney: elucidation of signal transduction pathways. J Clin Invest. 1989;83:336-342.
39. Miller WL, Redfield MM, Burnett JC Jr. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 1989;83:317-320.
40. Tomobe Y, Miyauchi T, Saito A, Yanagisawa M, Kimura S, Goto K, Masaki T. Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar-Kyoto rats. Eur J Pharmacol. 1988;152:373-374.
41. Suzuki T, Kumazaki T, Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 1993;191:823-830.
42. Hori S, Komatsu Y, Shigemoto R, Mizuno N, Nakanishi S. Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology. 1992;130:1885-1895.
43. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130-2134.
44. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res. 1993;27:2125-2129.
45. Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, Lin M, Adachi S, Akimoto H, Marumo F, Hiroe M. Natriuretic peptides inhibit angiotensin II-induced proliferation of cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest. 1995;96:1059-1065.
46. Momose N, Fukuo K, Morimoto S, Ogihara T. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. Hypertension. 1993;21:921-924.
47. Liu JJ, Casley D, Wojta J, Gallicchio M, Dauer R, Buxton BF, Johnston CI. Reduction of endothelin levels by the dihydropyridine calcium antagonist nisoldipine and a 'natural factor' in cultured human endothelial cells. J Hypertens. 1993;11:977-982.
48. 2+-currents in cultivated aortic myocytes. Biochem Biophys Acta. 1992;1160:95-104.
49. Owens GK, Rabinovitch PS, Schwartz SM. Smooth muscle cell hypertrophy versus hyperplasia in hypertension. Proc Natl Acad Sci U S A. 1981;78:7759-7763.
50. Neyses L, Nouskas J, Luyken J, Fronhoffs S, Oberdorf S, Pfeifer U, Williams RS, Sukhatme VP, Vetter H. Induction of immediate-early genes by angiotensin II and endothelin-1 in adult rat cardiomyocytes. J Hypertens. 1993;11:927-934.
51. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin or aldosterone. J Lab Clin Med. 1993;122:395-403.
52. Sun Y, Diaz-Arias A, Weber KT. Angiotensin converting enzyme, bradykinin and angiotensin II receptor binding in rat skin, tendon and heart valves: an in vitro quantitative autoradiographic study. J Lab Clin Med. 1994;123:372-377.
53. Michel J-B, Salzmann J-L, Cerol MDL, Dussaule J-C, Azizi M, Corman B, Camilleri JP, Corvol P. Myocardial effect of converting enzyme inhibition in hypertensive and normotensive rats. Am J Med. 1988;84(suppl 3A):12-21.
54. Hall JE. Control of sodium excretion by angiotensin II: intra-renal mechanisms and blood pressure regulation. Am J Physiol. 1986; 250:R960-R972.
55. Loutzenhiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics. Am J Physiol. 1985;249:F619-F629.
56. Loutzenhiser R, Epstein M, Hayashi K, Horton C. Direct visualization of effects of endothelin on the renal microvasculature. Am J Physiol. 1990;258:F61-F68.
57. Kato T, Kassab S, Wilkins FC Jr, Kirchner KA, Keiser J, Granger JP. Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension. 1995;25(part 2):883-887.